Contract notice
Section I: Contracting
authority
I.1) Name and addresses
Cardiff University
Procurement Services, McKenzie House, 30-36 Newport Road
Cardiff
CF24 0DE
UK
Telephone: +44 2920879648
E-mail: Buyline@cardiff.ac.uk
NUTS: UKL
Internet address(es)
Main address: http://www.cardiff.ac.uk/business/why-work-with-us/for-suppliers
Address of the buyer profile: https://www.sell2wales.gov.wales/search/Search_AuthProfile.aspx?ID=AA0258
I.3) Communication
The procurement documents are available for unrestricted and full direct access, free of charge at:
https://in-tendhost.co.uk/cardiffuniversity/aspx/Home
Additional information can be obtained from the abovementioned address
Tenders or requests to participate must be sent electronically to:
https://in-tendhost.co.uk/cardiffuniversity/aspx/Home
I.4) Type of the contracting authority
Body governed by public law
I.5) Main activity
Education
Section II: Object
II.1) Scope of the procurement
II.1.1) Title
Drug Development Framework
Reference number: CU258
II.1.2) Main CPV code
73111000
II.1.3) Type of contract
Services
II.1.4) Short description
Cardiff University are ranked 2nd nationally for the impact of their research and are among the top five universities in the UK for research excellence. Cardiff University has a thriving and innovative research culture, with research that has real impact and makes a positive difference to the world. As part of this, the University is translating fundamental discoveries in disease processes to develop new medicines to meet unmet clinical needs.
Cardiff University is looking for companies with an innovative outlook and recognised expertise in supporting drug-discovery projects from early screening (electrophysiology and in vitro DMPK) to delivering de-risked novel molecules to clinical trials. Successful companies will be committed to the principles of the NC3Rs and will add value to our work by providing high-quality data for informing the drug-discovery pipeline.
II.1.6) Information about lots
This contract is divided into lots:
Yes
Tenders may be submitted for all lots
II.2) Description
Lot No: 1
II.2.1) Title
Electrophysiology Services
II.2.2) Additional CPV code(s)
73111000
II.2.3) Place of performance
NUTS code:
UKL22
II.2.4) Description of the procurement
We require providers for electrophysiology services relevant to neuroscience drug development.
Currently we require validated ion channel assays for GABAA and NMDA modulators, on an automated electrophysiology platform, with QC and report generation.
In the near future, it is likely we will require a range of other ion channel assays, as well as manual patch clamp services. We may also want to purchase ion channel expressing cell lines (under a MTA).
II.2.5) Award criteria
Price is not the only award criterion and all criteria are stated only in the procurement documents
II.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Duration in months: 24
This contract is subject to renewal: Yes
Description of renewals:
This Framework shall run for an initial period of two years. Where appropriate, and subject to agreement, the Framework may be extended in one-year increments provided that the total life of the Framework does not exceed four years (2+1+1).
II.2.9) Information about the limits on the number of candidates to be invited
II.2.10) Information about variants
Variants will be accepted:
No
II.2.11) Information about options
Options:
No
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
Yes
Lot No: 2
II.2.1) Title
In-vivo assays
II.2.2) Additional CPV code(s)
73111000
II.2.3) Place of performance
NUTS code:
UKL22
II.2.4) Description of the procurement
We require providers for in-vivo assays, most usually with oral administration. We currently require reliable assays for pro-cognitive and anxiolytic effects. In the future, we may require assays to demonstrate other drug modulated effects, such as, but not limited to, an anti-depressive effect.
II.2.5) Award criteria
Price is not the only award criterion and all criteria are stated only in the procurement documents
II.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Duration in months: 24
This contract is subject to renewal: Yes
Description of renewals:
This Framework shall run for an initial period of two years. Where appropriate, and subject to agreement, the Framework may be extended in one-year increments provided that the total life of the Framework does not exceed four years (2+1+1).
II.2.9) Information about the limits on the number of candidates to be invited
II.2.10) Information about variants
Variants will be accepted:
No
II.2.11) Information about options
Options:
No
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
Yes
Lot No: 3
II.2.1) Title
In-vitro drug metabolism (ADME-Tox) services
II.2.2) Additional CPV code(s)
73111000
II.2.3) Place of performance
NUTS code:
UKL22
II.2.4) Description of the procurement
We require providers of in-vitro drug metabolism (ADME-Tox) services as part of our drug development pipeline. This includes, but is not limited to, measures of metabolism, permeability and transporters, physicochemical properties, protein binding and toxicology.
II.2.5) Award criteria
Price is not the only award criterion and all criteria are stated only in the procurement documents
II.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Duration in months: 24
This contract is subject to renewal: Yes
Description of renewals:
This Framework shall run for an initial period of two years. Where appropriate, and subject to agreement, the Framework may be extended in one-year increments provided that the total life of the Framework does not exceed four years (2+1+1).
II.2.9) Information about the limits on the number of candidates to be invited
II.2.10) Information about variants
Variants will be accepted:
No
II.2.11) Information about options
Options:
No
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
Yes
Lot No: 4
II.2.1) Title
In-vivo pharmacokinetics (PK) and toxicology
II.2.2) Additional CPV code(s)
73111000
II.2.3) Place of performance
NUTS code:
UKL22
II.2.4) Description of the procurement
We require providers of in-vivo drug metabolism (ADME-Tox) services as part of our drug development pipeline.
II.2.5) Award criteria
Price is not the only award criterion and all criteria are stated only in the procurement documents
II.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Duration in months: 24
This contract is subject to renewal: Yes
Description of renewals:
This Framework shall run for an initial period of two years. Where appropriate, and subject to agreement, the Framework may be extended in one-year increments provided that the total life of the Framework does not exceed four years (2+1+1).
II.2.9) Information about the limits on the number of candidates to be invited
II.2.10) Information about variants
Variants will be accepted:
No
II.2.11) Information about options
Options:
No
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
Yes
Section III: Legal, economic, financial and technical information
III.1) Conditions for participation
III.1.2) Economic and financial standing
Selection criteria as stated in the procurement documents
III.1.3) Technical and professional ability
Selection criteria as stated in the procurement documents
III.2) Conditions related to the contract
Section IV: Procedure
IV.1) Description
IV.1.1) Type of procedure
Open procedure
IV.1.3) Information about a framework agreement or a dynamic purchasing system
The procurement involves the establishment of a framework agreement with several operators.
Envisaged maximum number of participants to the framework agreement: 10
IV.1.8) Information about Government Procurement Agreement (GPA)
The procurement is covered by the Government Procurement Agreement:
Yes
IV.2) Administrative information
IV.2.2) Time limit for receipt of tenders or requests to participate
Date:
08/06/2020
Local time: 12:00
IV.2.4) Languages in which tenders or requests to participate may be submitted
EN
CY
IV.2.6) Minimum time frame during which the tenderer must maintain the tender
Duration in months: 3 (from the date stated for receipt of tender)
IV.2.7) Conditions for opening of tenders
Date:
08/06/2020
Local time: 12:00
Section VI: Complementary information
VI.1) Information about recurrence
This is a recurrent procurement:
No
VI.2) Information about electronic workflows
Electronic ordering will be used
Electronic invoicing will be accepted
Electronic payment will be used
VI.3) Additional information
Bidders will need to create an account via In-Tend (https://in-tendhost.co.uk/cardiffuniversity/aspx/Home) in order to view the tender documents.
Under the terms of this contract the successful supplier(s) will be required to deliver Community Benefits in support of the authority’s economic and social objectives. Accordingly, contract performance conditions may relate in particular to social and environmental considerations. The Community Benefits included in this contract are:
As stated within the tender document
(WA Ref:101107)
The buyer considers that this contract is suitable for consortia.
VI.4) Procedures for review
VI.4.1) Review body
High Court
Royal Courts of Justice, The Strand
London
WC2A 2LL
UK
Telephone: +44 2079477501
VI.5) Date of dispatch of this notice
14/04/2020